Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Lilly Cuts Low-Dose Zepbound Price Up to 20% for Cash-Pay Buyers

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...

Eli Lilly cuts Zepbound price to widen access for obesity drug

Eli Lilly said it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more ...

Eli Lilly Lowers Price of Zepbound Single-Dose Vials

Eli Lilly cut prices of its Zepbound drug single-dose vials on its direct-to-consumer platform after it lowered prices of its multi-dose pens last month. The 2.5 milligram starting dose of Zepbound ...
24/7 Wall St.

Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump

Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally ...

Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...